Direct-to-patient research: Opportunity brings challenges.

Direct-to-patient (DTP) research offers promising alternatives to traditional models, potentially improving population-level data collection to understand disease initiation, progression, and response to treatment. Patients quickly joined CureCloud, yet several unanticipated outcomes led the MMRF to halt enrollment earlier than projected.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Recent reports and commentaries on DTP research, particularly in cancer, suggest major strides forward for both common and rare cancer research and for addressing better data access and representation that can limit the utility of clinical trials.
• 2 The Multiple Myeloma Research Foundation's (MMRF) CureCloud® Research Initiative built a DTP model for clinical study including genomics, with the goal of creating a platform to provide myeloma patients with their own genomic profile while building a database that combines genomic insights with clinical data to identify trends and support further developments.
• 3 Patients quickly joined CureCloud, yet several unanticipated outcomes led the MMRF to halt enrollment earlier than projected.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: